Skip to main content
. 2019 Nov 1;15:3051–3060. doi: 10.2147/NDT.S218450

Table 1.

Demographic Data, Health Condition, And Self-Reported Inventory Of Patients With Breast Cancer (N = 145)

Characteristics Mean± SD/N (%)
Age, years 52.25±10.45
BMI, kg/m2 24.22±4.11
Year of education 10.77±3.95
Marital status, married 115 (79.3)
Employment 75 (51.7)
Menopause Status (Menopause) 106 (73.1)
Comorbidity
 Psychiatric history 27 (18.6)
 Diabetes 10 (6.9)
 Hypertension 29 (20.0)
Cancer stage
 0 25 (17.4)
 1 44 (30.6)
 2 57 (39.6)
 3 18 (12.4)
Systemic treatments
 Chemotherapy 38 (26.2)
 Radiotherapy 46 (31.7)
 Hormone therapy 61 (42.1)
Family History
 Breast Cancer 30 (20.7)
 Psychiatric disorders 13 (9.0)
Surgical procedure
 Partial mastectomy 114 (79.2)
 Total mastectomy 30 (20.8)
Cancer subtypes
 ER, positive 114 (78.6)
 PR, positive 97 (66.9)
 Her2_neu, negative 90 (62.1)
 Her2_neu, positive 25 (17.2)
 Her2_neu, equivocal 28 (19.3)
 Lymph node involvement 43 (29.7)
Self-report inventory
 Family support (family APGAR score) 6.26±3.16
 Depression (PHQ-9) 4.79±4.47
 EQ-VAS 71.91±19.00
 FACT-Cog, total score 115.94±14.26
 PTSD (SPAN-C) 0.77±2.01
 PTGI (n=108), total scores 32.54±26.17
 Chronic pain (score) 1.37±2.24
 Fatigue (BFI, n=108)
 Fatigue severity 4.71±6.42
 Fatigue interference 3.31±5.63
 Alexithymia (TAS, n=108) 55.31±5.90
 Anxiety symptoms (HADS) (n=108) 3.85±3.78

Note: There was one missing piece of data on cancer stage and surgical procedure.

Abbreviations: BFI, Brief Fatigue Inventory; ER, estrogen receptor; HADS-A, Hospital Anxiety and Depression Scale-Anxiety symptoms; Her2, human epidermal growth factor receptor; PHQ-9, Patient Health Questionnaire-9; PR, progesterone receptor; PTGI, Post-traumatic Growth Inventory; TAS, Toronto Alexithymia Scale; VAS, visual analog scale.